Results 21 to 30 of about 16,733 (229)

Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli

International Journal of Antimicrobial Agents, 2023
Aztreonam/avibactam is being developed on the rationale that aztreonam evades metallo-β-lactamases (MBLs) whilst avibactam protects against co-produced serine β-lactamases.
David M Livermore, Shazad Mushtaq
exaly   +2 more sources

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

European Journal of Clinical Pharmacology, 2023
A series of iterative population pharmacokinetic (PK) modeling and probability of target attainment (PTA) analyses based on emerging data supported dose selection for aztreonam-avibactam, an investigational combination antibiotic for serious Gram ...
Shampa Das, Todd Riccobene, T. Carrothers, James G. Wright, Merran Macpherson, Andrew Cristinacce, L. Mcfadyen, Rujia Xie, Alison Luckey, Susan R. Raber   +9 more
semanticscholar   +3 more sources

Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism

mSystems, 2020
Aztreonam-avibactam is a promising antimicrobial combination against multidrug-resistant organisms, such as carbapenemase-producing Enterobacterales. Resistance to aztreonam-avibactam has been found, but the resistance mechanism remains poorly studied ...
Ke Ma, Yu Feng, Alan McNally, Zhiyong Zong   +3 more
doaj   +3 more sources

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

BMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Timothy B. Doyle, Mariana Castanheira   +4 more
doaj   +2 more sources

Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). [PDF]

J Antimicrob Chemother
Objectives To evaluate the in vitro activity of aztreonam/avibactam against Enterobacterales from European medical centres during the 5-year period prior to its approval for clinical use in Europe.
Sader HS, Kimbrough JH, Winkler ML, Castanheira M, Mendes RE.   +4 more
europepmc   +2 more sources

Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017-2022). [PDF]

Open Forum Infect Dis
Background Carbapenem-resistant Enterobacterales (CREs) are a major public health threat because treatment options are limited. The predominant resistance mechanism in CREs is the production of carbapenemases.
Papp-Wallace KM, Sader HS, Maher JM, Kimbrough JH, Castanheira M.   +4 more
europepmc   +2 more sources

Cost-Effectiveness Analysis of Aztreonam-Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain. [PDF]

Infect Dis Ther
Aztreonam–avibactam (ATM-AVI) is the first β-lactam/β-lactamase inhibitor antibiotic for treating serious infections caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamases (MBL)-Enterobacterales.
Aguilar G, Ruiz-Garbajosa P, Periañez Parraga L, Maroto-Díaz M, de Ceano-Vivas MDC, Villacampa Lordan A, Arranz Gonzalo S, de Lossada Juste A, Moya-Alarcón C, Gheorghe M, Torre-Cisneros J.   +10 more
europepmc   +2 more sources

Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates [PDF]

Antimicrobial Agents and Chemotherapy, 2020
Metallo-β-lactamase (MBL)-producing Escherichia coli isolates resistant to the newly developed β-lactam/β-lactamase inhibitor drug combination aztreonam-avibactam (ATM-AVI) have been reported. Here, we analyzed a series of 118 clinical MBL-producing E.
Mustafa Sadek, Laurent Poirel, Patrice Nordmann   +2 more
exaly   +4 more sources

Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals

Journal of Global Antimicrobial Resistance
Objectives: Enterobacterales isolates producing β-lactamases are widespread and threaten the use of β-lactams. This study evaluated the activity of aztreonam-avibactam and comparator antimicrobial agents against Enterobacterales isolates producing common
Lalitagauri M Deshpande, Timothy B Doyle, Helio S Sader, Mariana Castanheira   +3 more
doaj   +2 more sources

In vitro activity of aztreonam–avibactam against metallo-β-lactamase-producing Enterobacteriaceae—A multicenter study in China [PDF]

International Journal of Infectious Diseases, 2020
Objectives: To study the molecular epidemiology of clinical metallo-β-lactamase (MBL)-producing Enterobacteriaceae isolates in China and to evaluate the antimicrobial susceptibility of MBL-Enterobacteriaceae isolates to aztreonam–avibactam.
Biying Zhang, Zhichen Zhu, Wei Jia, Fen Qu, Bin Huang, Bin Shan, Hua Yu, Yiwei Tang, Liang Chen, Hong Du   +9 more
doaj   +3 more sources